Fulgent Genetics, Inc.

Fulgent Genetics, Inc. ( FLGT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Karan Patel - Piper Sandler & Co., Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Fulgent Genetics Q3 2026 Conference Call and Webcast Call. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.

Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift results. The company reaffirmed its full-year revenue forecast and narrowed its projected loss.

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.14 per share a year ago.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Results: Revenue of $90.4 million GAAP loss of $13.2 million, or $(0.48) per share Non-GAAP loss of $2.4 million, or $(0.09) per share Adjusted EBITDA loss of $7.5 million No.